These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34781870)

  • 61. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva).
    Darmani NA; Crim JL
    Pharmacol Biochem Behav; 2005 Jan; 80(1):35-44. PubMed ID: 15652378
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Legal controls on cannabimimetics: an international dilemma?
    King LA
    Drug Test Anal; 2014; 6(1-2):80-7. PubMed ID: 23881527
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.
    Waugh J; Najafi J; Hawkins L; Hill SL; Eddleston M; Vale JA; Thompson JP; Thomas SH
    Clin Toxicol (Phila); 2016 Jul; 54(6):512-8. PubMed ID: 27091041
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
    Sholler DJ; Huestis MA; Amendolara B; Vandrey R; Cooper ZD
    Pharmacol Biochem Behav; 2020 Dec; 199():173059. PubMed ID: 33086126
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market.
    Brandon AM; Antonides LH; Riley J; Epemolu O; McKeown DA; Read KD; McKenzie C
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33807614
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Toxicological properties of Δ9-tetrahydrocannabinol and cannabidiol.
    Černe K
    Arh Hig Rada Toksikol; 2020 Mar; 71(1):1-11. PubMed ID: 32597140
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Emerging role of cannabinoids and synthetic cannabinoid receptor 1/cannabinoid receptor 2 receptor agonists in cancer treatment and chemotherapy-associated cancer management.
    Shah SA; Gupta AS; Kumar P
    J Cancer Res Ther; 2021; 17(1):1-9. PubMed ID: 33723124
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs.
    Banister SD; Kevin RC; Martin L; Adams A; Macdonald C; Manning JJ; Boyd R; Cunningham M; Stevens MY; McGregor IS; Glass M; Connor M; Gerona RR
    Drug Test Anal; 2019 Jul; 11(7):976-989. PubMed ID: 30838752
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues.
    Bonaccorso S; Metastasio A; Ricciardi A; Stewart N; Jamal L; Rujully NU; Theleritis C; Ferracuti S; Ducci G; Schifano F
    Brain Sci; 2018 Jul; 8(7):. PubMed ID: 30011896
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Terpenoids, Cannabimimetic Ligands, beyond the
    Gonçalves ECD; Baldasso GM; Bicca MA; Paes RS; Capasso R; Dutra RC
    Molecules; 2020 Mar; 25(7):. PubMed ID: 32235333
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
    Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
    J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11.
    Kevin RC; Cairns EA; Boyd R; Arnold JC; Bowen MT; McGregor IS; Banister SD
    Front Psychiatry; 2022; 13():1048836. PubMed ID: 36590635
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
    Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
    Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Synthetic cannabinoids as drugs of abuse.
    Ashton JC
    Curr Drug Abuse Rev; 2012 Jun; 5(2):158-68. PubMed ID: 22530798
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays.
    Grafinger KE; Vandeputte MM; Cannaert A; Ametovski A; Sparkes E; Cairns E; Juchli PO; Haschimi B; Pulver B; Banister SD; Stove CP; Auwärter V
    Drug Test Anal; 2021 Jul; 13(7):1412-1429. PubMed ID: 33908179
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
    Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
    Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA.
    Finlay DB; Manning JJ; Ibsen MS; Macdonald CE; Patel M; Javitch JA; Banister SD; Glass M
    ACS Chem Neurosci; 2019 Oct; 10(10):4350-4360. PubMed ID: 31513380
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Behavioral effects of cannabinoid agents in animals.
    Chaperon F; Thiébot MH
    Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synthetic cannabinoid receptor agonists: Analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233.
    Brandt SD; Kavanagh PV; Westphal F; Dreiseitel W; Dowling G; Bowden MJ; Williamson JPB
    Drug Test Anal; 2021 Jan; 13(1):175-196. PubMed ID: 32880103
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.